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ABSTRACT
Statistical Inference for Costs and Incremental
Cost-Effectiveness Ratios with Censored Data. (May 2012)
Shuai Chen, B.S., Peking University
Co–Chairs of Advisory Committee: Dr. Hongwei Zhao
Dr. Lan Zhou
Cost-effectiveness analysis is widely conducted in the economic evaluation of new
treatment options. In many clinical and observational studies of costs, data are
often censored. Censoring brings challenges to both medical cost estimation and
cost-effectiveness analysis. Although methods have been proposed for estimating the
mean costs with censored data, they are often derived from theory and it is not always
easy to understand how these methods work. We provide an alternative method for
estimating the mean cost more efficiently based on a replace-from-the-right algorithm,
and show that this estimator is equivalent to an existing estimator based on the inverse
probability weighting principle and semiparametric efficiency theory. Therefore, we
provide an intuitive explanation to a theoretically derived mean cost estimator.
In many applications, it is also important to estimate the survival function of
costs. We propose a generalized redistribute-to-the right algorithm for estimating the
survival function of costs with censored data, and show that it is equivalent to a simple
weighted survival estimator of costs based on inverse probability weighting techniques.
Motivated by this redistribute-to-the-right principle, we also develop a more efficient
survival estimator for costs, which has the desirable property of being monotone, and
more efficient, although not always consistent. We conduct simulation to compare
iv
our method with some existing survival estimators for costs, and find the bias seems
quite small. Thus, it may be considered as a candidate for survival estimator for costs
in a real setting when the censoring is heavy and cost history information is available.
Finally, we consider one special situation in conducting cost-effectiveness analysis,
when the terminating events for survival time and costs are different. Traditional
methods for statistical inference cannot deal with such data. We propose a new
method for deriving the confidence interval for the incremental cost-effectiveness ratio
under this situation, based on counting process and the general theory for missing
data process. The simulation studies show that our method performs very well for
some practical settings. Our proposed method has a great potential of being applied
to a real setting when different terminating events exist for survival time and costs.
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1CHAPTER I
INTRODUCTION
Due to skyrocketing of health care costs and limited resource available, economic
evaluation of new treatments has received more and more attention. To compare
different treatments, cost-effectiveness analysis helps evaluate the economic impact
of the new treatment and its effects on health care, in the hope of finding an effective
treatment without causing too much a burden to the society.
The analysis of cost data involves some unique challenges that require advanced
statistical methodologies, especially when costs are censored. For example, random-
ized clinical trials often enroll subjects over a broad time period, but the trial ends at
a fixed time point. As a result, subjects are observed for differing amounts of time,
and those who are still alive at the end of the study are considered censored. Thus, we
cannot observe further costs after censored time for those patients. Besides, censoring
poses a unique problem for cost estimation due to the “induced informative censor-
ing” problem, first noted by Lin et al. (1997). Traditional survival analysis methods
assume that the censoring time is independent of the survival time (conditional on
some covariates). However, the costs at censoring time are no longer independent of
the potential total costs. For example, a healthier patient will accumulate costs more
slowly, and therefore will have less costs at the censoring time, and at the potential
event time (Lin, 2003). Thus, many standard approaches for survival analysis (e.g.,
Kaplan-Meier estimator and Cox regression model) are not valid for the analysis of
cost data.
Therefore, many researchers have proposed methods for estimating the mean med-
 This thesis follows the style of Biometrics.
2ical costs, and most of them focus on the time-restricted medical costs, i.e., the costs
accumulated within a time limit. Although many estimators for the mean costs have
appeared in the literature, they are often based on theory, and it is not always easy
for practitioners to understand why these methods work. To alleviate this situation,
Zhao et al. (2011) established a mathematical equivalency between the BT estima-
tor for the mean costs (Bang and Tsiatis, 2000), and a replace-from-the-right (RR)
algorithm (Pfeifer and Bang, 2005). Thus, the BT estimator, which is based on the
inverse probability weighting technique (Horvitz and Thompson, 1952), has a more
intuitive explanation from the RR algorithm. Motivated by this idea, we will ex-
tend this work by proposing a modified RR algorithm, the RRimp method, which
utilizes the cost history information and is therefore generally more efficient than the
RR estimator. We will provide a proof of the mathematical equivalence between the
RRimp method and an existing estimator for the mean costs, the ZT estimator (Zhao
and Tian, 2001). Due to a lack of a theoretical background for understanding the BT
and ZT estimators, some practitioners might be reluctant to use them. With the easy
interpretation of the RR and RRimp estimators, and established equivalency between
these estimators and the BT, ZT estimators, we believe these estimators will become
more popular among practitioners.
Furthermore, since cost data are often highly skewed, it is more desirable to estimate
the median and other quantiles of the costs. These quantities can be available if we
can estimate the survival function of costs. Using the original redistribute-to-the right
algorithm, we propose a RRS (abbreviated as RRS for survival estimator) survival
estimator for costs, and show that it is equivalent to a simple weighted (SW) survival
estimator for costs (Zhao and Tsiatis, 1997; Zhao et al., 2012). We extend this method
and propose a RRimpS survival estimator. Further simulation studies are conducted
to compare this RRimpS survival estimator with the RRS survival estimator (or
3equivalent SW estimator), and a more efficient ZTS survival estimator (Zhao and
Tsiatis, 1997; Zhao et al., 2012).
Moreover, in performing cost-effectiveness analysis with censored data, there have
been several measures proposed to evaluate the treatments (Chaudhary and Sterns,
1996; Heitjan, 2000; Willan and Lin, 2001; Briggs et al., 2002; O’Brien and Briggs,
2002; Willan and Briggs, 2006). Among them the incremental cost-effectiveness ratio
(ICER) is a widely used criterion. The ICER is defined as the costs incurred for sav-
ing an additional year of life. When one treatment has a significant effectiveness over
another treatment but is more expensive, this measure is especially useful. Usually
the effectiveness are defined as the survival time for patients, and therefore the end-
points for costs and effectiveness are the same. However, it is commonly encountered
in clinical studies that we need to use different endpoints for costs and effectiveness
estimation. For example, a new strategy might prevent the heart failure event. Hence,
it may extend the heart-failure free survival time, but not overall survival time. How-
ever, we are still interested in the costs estimation up to death. In this situation, we
are interested in estimating the ICER based on the heart-failure free survival time but
costs accumulated until death. Although the construction for the confidence intervals
(CI) of usual ICER with the same terminating points has been studied much, there
are no theoretical results for research on this ICER and its CI which allow different
terminating events. Thus, we propose a method to handle this problem.
The remainder of the thesis is organized as followed. In Chapter II, we will discuss
the mean cost estimators with corresponding intuitive explanation, as well as the
survival function estimators for cost. In Chapter III, we will concentrate on cost-
effectiveness analysis, and show how to handle the problem of ICER with different
terminating events. The Chapter IV is the Summary of this thesis, which summarizes
the innovative methods we proposed in this thesis.
4CHAPTER II
ESTIMATING THE MEAN COST AND SURVIVAL FUNCTIONS
FOR COSTS
1. Introduction
Economic evaluation of new treatments has received more and more attention, due
to skyrocketing of health care costs and limited resource available. Cost-effectiveness
study is often carried out to evaluate new treatments in the hope of finding an effec-
tive treatment without causing too much a burden to the society. In clinical trials and
in observational studies, survival time and health costs are often censored for admin-
istrative reasons, since not all patients can be observed until they experience some
events, such as death, or disease relapse. Censoring poses a unique problem for cost
estimation due to the “induced informative censoring” problem, first noted by Lin
et al. (1997). Traditional survival analysis methods assume that the censoring time
is independent of the survival time (conditional on some covariates). However, the
costs at censoring time are no longer independent of the total uncensored costs. For
example, a healthier patient will accumulate costs more slowly, and therefore will have
less costs at the censoring time, and at the potential event time (Lin, 2003). Thus,
many standard approaches for survival analysis, such as the Kaplan-Meier estimator
(Kaplan and Meier, 1958), or the Cox regression model (Cox, 1972), are not valid for
the analysis of cost data. Many researchers have proposed methods for estimating the
mean medical costs, and most of them focus on the restricted medical costs, i.e., the
costs accumulated within a time limit. Among them, Lin et al. (1997) proposed esti-
mators via survival probability weighting using partitioned time intervals; Bang and
Tsiatis (2000) proposed consistent estimators using the inverse probability weighting
5technique; Zhao and Tian (2001) proposed a more efficient estimator. Later, Zhao
et al. (2007) discovered some conditions under which the estimators without using
cost history, and estimators using cost history become identical within each class.
Although many estimators for the mean costs have appeared in the literature, they
are often based on theory, and it is not always easy for practitioners to understand
why these methods work. To alleviate this situation, Zhao et al. (2011) established a
mathematical equivalency between the BT estimator for the mean costs (Bang and
Tsiatis, 2000), and a replace-from-the-right (RR) algorithm (Pfeifer and Bang, 2005).
Thus, the BT estimator, which is based on the inverse probability weighting tech-
nique (Horvitz and Thompson, 1952), has a more intuitive explanation from the RR
algorithm. Motivated by this idea, we will propose a modified RR algorithm, the
RRimp method, which utilizes the cost history information and is therefore generally
more efficient than the RR estimator. We will provide a proof of the mathemati-
cal equivalence between the RRimp method and an existing estimator for the mean
costs, the ZT estimator (Zhao and Tian, 2001). The ZT estimator was derived from
complicated theory. Therefore, the RRimp algorithm will provide an insight on how
the ZT estimator works and will eventually help promote its application in practice.
Since cost data are often highly skewed, with most people incur little costs, but
a few people accumulate huge costs, it is often desirable to estimate the median
and other quantiles of the costs. These quantities can be readily available if we can
estimate the survival function of costs. Using the original redistribute-to-the right
algorithm, we propose a RRS (abbreviated as RRS for survival estimator) survival
estimator for costs, and show that it is equivalent to a simple weighted (SW) survival
estimator for costs (Zhao and Tsiatis, 1997; Zhao et al., 2012). We extend this method
and propose a RRimpS survival estimator. We conduct simulation studies to compare
this RRimpS survival estimator with the RRS survival estimator (or equivalent SW
6estimator), and a more efficient ZTS survival estimator (Zhao and Tsiatis, 1997; Zhao
et al., 2012). We will discuss our findings in the Conclusion section.
2. Notation and Assumptions
For the ith individual in the study, i = 1, 2, . . . , n, we define Ti as the survival time
from the beginning of the study until the occurrence of some event, e.g. death, or
disease relapse. The censoring time for the ith individual is denoted as Ci. We can
observe either the survival time or the censoring time, whichever is smaller, i.e. we
observe the follow-up time Xi = min(Ti, Ci) and the indicator variable ∆i = I(Ti ≤
Ci). We define Mi(t) as the accumulated cost of patient i from time 0 to t. For some
real applications, we only observe the total cost Mi = Mi(Xi). However, in other
studies, we may know the entire cost history, Mi(t), 0 < t < Xi.
We assume that the censoring variable is independent of the survival time and
cost accumulation process, which is often satisfied in well-conducted clinical trials
and some observational studies where censoring is caused mainly by administrative
reasons. Due to the presence of censoring, the marginal distribution of cost may be
nowhere identifiable without making some parametric assumptions (Huang, 2002).
Hence we adopt an approach that focuses on the accumulated cost by a time limit L,
where L is chosen such that a reasonable amount of information is still available at
that time. A consequence of using such a restriction is that a survival time larger than
L can be considered equivalently as having an event at time L, i.e. TLi = min(Ti, L)
(we still use Ti for notational convenience).
We consider the problem of estimating the mean cost, µ = E{Mi(Ti)}, and the
survival function of cost, S(x) = Pr{Mi(Ti) > x}, for costs accumulated to a time L.
For reasons that will become clear later, we also need to define the survival function
7for the event time as ST (t) = Pr(Ti > t), and the survival function for the censoring
time as K(t) = Pr(Ci > t).
3. Estimating the Mean Cost
3.1. Without Using Cost History: The BT Estimator and Its Equivalent RR Esti-
mator
For estimation of mean cost accumulated over time L with censoring data, a consistent
estimator was proposed by Bang and Tsiatis (2000) based on the inverse probability
weighting technique:
µˆBT =
1
n
n∑
i=1
∆iMi
Kˆ(Ti)
, (2.1)
where Mi is the total observed cost for the ith individual, and Kˆ(Ti) is the Kaplan-
Meier estimator for the survival function of the censoring time, K(t) = Pr(Ci > t).
K(Ti) represents the probability that a subject is uncensored at Ti. The basic idea
of the BT estimator is that each complete observation represents potential 1/Kˆ(Ti)
observations who might be censored.
Even though the BT estimator is easy to obtain mathematically, it is not very
intuitive for people to understand why it works. The replace-from-the-right (RR)
estimator proposed by Pfeifer and Bang (2005), on the other hand, is a more intuitive
estimator. To explain the main idea of the RR method, first we note that without
censoring, a mean cost estimator is simply the average of costs from all observations.
When a subject is censored, we only know that this subject lives longer than his
censoring time, but we do not have information on his total cost. In the RR algorithm,
we replace this subject’s cost by an average of costs from those individuals who
survived longer than this subject. Specifically, a RR estimator for the mean costs can
be obtained by first arranging all the subjects from the smallest observed time to the
8largest observed time (if there is a tie, put the events a little before the censored).
We then move from the right (the largest observation time) to the left (the smallest
observation time). When we encounter the largest censored observation, say, at time
Ci, we replace its costs by the average of costs from all the observations to its right,
MRRi =
∑n
j=1 I(Xj > Ci)Mj∑n
j=1 I(Xj > Ci)
. (2.2)
We move to the left and repeat this process of replacing all the censored costs with
the average of all upstream costs (some of these are real costs and some are replaced
costs). The RR mean cost estimator is simply an average of all the costs from both
complete observations and censored observations (replaced costs), i.e.
µˆRR =
1
n
n∑
i=1
{∆iMi + (1−∆i)MRRi }. (2.3)
Although the BT estimator (2.1) and the RR method (2.3) look quite different –
the former is based on a well-known theory, and the latter makes intuitive sense, it is
quite amazing that the two estimators are actually mathematically equivalent. The
detailed proof was provided in Zhao et al. (2011).
3.2. Using the Cost History: The ZT Estimator and Its Equivalent RRimp Estimator
The BT estimator and its equivalent RR algorithm use only the total cost information
from uncensored subjects. Hence, they are not very efficient. An improved estimator
was proposed by Zhao and Tian (2001), which utilizes cost history information from
both censored and uncensored observations. Therefore the ZT estimator is often more
efficient. The ZT estimator has the following simplified form (Pfeifer and Bang, 2005):
µˆZT =
1
n
n∑
i=1
∆iMi
Kˆ(Ti)
+
1
n
n∑
i=1
(1−∆i)[Mi(Ci)−M(Ci)]
Kˆ(Ci)
, (2.4)
9where M(Ci) =
∑n
j=1 I(Xj ≥ Ci)Mj(Ci)/
∑n
j=1 I(Xj ≥ Ci), which is the average
accumulative cost at time Ci of those subjects who are alive at Ci.
The ZT estimator consists of two terms. The first term is the BT estimator. The
second term is constructed using cost history information, which can be viewed as
an adjustment term. The ZT estimator gains more efficiency by adjusting the BT
estimator based on the difference of censored costs and the average accumulated
costs at the same time point. Zhao and Tian (2001) established the large sample
property for this estimator. Furthermore, Zhao et al. (2007) described the conditions
under which this estimator is equivalent to the partitioned Bang and Tsiatis (2000)
estimator, as well as the two estimators of medical costs proposed by Lin et al. (1997).
Since the BT estimator has an intuitive explanation through the RR algorithm, it
is natural to wonder whether the ZT estimator has a similar intuitive explanation. As
a result, we propose a RRimp algorithm, which makes intuitive sense, and later we
show that it is equivalent to the ZT estimator. In contrast to the simple RR method,
which depends only on the total costs from complete observations, the RRimp algo-
rithm uses the cost history information. Intuitively, for a censored subject, we already
know his accumulated cost before censoring. Hence, the only thing we need to esti-
mate is his cost after the censoring time point. We can achieve that by the average
of additional costs accumulated by those subjects who survive longer. The detailed
RRimp estimator can be described as follows. First arrange all the subjects from the
smallest observed time to the largest observed time. If there is a tie, we assume events
happen shortly before censoring times. Since we focus on time-restricted costs esti-
mation, we assume that the individual with the largest observed time is uncensored.
Starting from the right (the largest observed time) we move to the left. We first find
the largest censoring time, denoted as Ci. We replace the cost for this observation by
a summation of his observed cost and the average additional accumulated costs from
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all subjects who have a larger survival time, i.e.
MRRimpi =Mi(Ci) +
∑n
j=1 I(Xj > Ci){Mj −Mj(Ci)}∑n
j=1 I(Xj > Ci)
. (2.5)
We then move to the second largest censoring time and perform the same replacement
procedure, where we use the replaced cost for the largest censoring time in calculating
the average. We move to the left and repeat this process until we replace all the
censored costs. The RRimp estimator is then obtained by an average of costs from
all complete observations (real costs) and the censored observations (replaced costs),
i.e.
µˆRRimp =
1
n
n∑
i=1
{∆iMi + (1−∆i)MRRimpi }. (2.6)
We illustrate this algorithm using a simple example in Figure 1. Suppose we observe
the following data: X = {1, 2, 3, 4, 5}, ∆ = {1, 0, 1, 0, 1}, and their accumulated costs
Mi(·) are shown in the figure below. Here the 2nd and 4th subjects are censored.
In Step 1, we try to obtain the replacement cost for subject 4. Since subject 5 is
the only one surviving longer than subject 4. the replacement cost for subject 4 is
equal to the summation of the censored cost of subject 4 (=60) and the additional
accumulated cost of subject 5 from time X4 to X5 (= 40−30), which is 70. Similarly,
in Step 2 we try to obtain the replacement cost for subject 2 by adding the observed
cost of subject 2 (=50) and the average of additional costs after time X2 for subject 3
(=100-60, real costs), subject 4 (=70-20, replaced costs) and subject 5 (=40-10, real
costs), which is equal to 90. Therefore, the mean cost estimated from the RRimp
method gives an estimate of 62, as shown in the graph below.
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Xi = 1 2 3 4 5
x o x o x
M1(·) =10
M2(·) =20 50
M3(·) =30 60 100
M4(·) =10 20 40 60
M5(·) =5 10 20 30 40
Step 1: (MRRimp4 ) 70{= 60 + (40− 30)}
Step 2: (MRRimp2 ) 90{= 50 + [(100− 60) + (70− 20) + (40− 10)]/3}
µˆRRimp = (10 + 90 + 100 + 70 + 40)/5 = 62.
Figure 1. An example for the RRimp mean cost estimator.
Meanwhile, the ZT estimator of the mean cost obtained from the same data set is:
µˆZT =
1
5
5∑
i=1
∆iMi
Kˆ(Ti)
+
1
5
5∑
i=1
(1−∆i)[Mi(Ci)−M(Ci)]
Kˆ(Ci)
=
1
5
(
10
1
+
100
3/4
+
40
3/8
) +
1
5
(
50− 35
3/4
+
60− 45
3/8
)
=
1
5
(10 + 400/3 + 320/3) +
1
5
(20 + 40)
= 50 + 12 = 62,
where the Kaplan-Meier estimates for K(t) = Pr(Ci > t) are Kˆ(Xi)=(1, 3/4, 3/4,
3/8, 3/8), at Xi = {1, 2, 3, 4, 5}, and M(Ci) = {35, 45}, at Ci = {2, 4}, respectively.
Hence, We obtain exactly the same estimate for the mean cost using the ZT estimator
and the RRimp method using this data set. Actually they are always the same no
matter what data sets we use. A mathematical proof of the equivalence of these two
estimators is provided in Appendix A.
In summary, the RRimp method works as follows. Due to censoring, we use the
upstream complete costs to infer the censored cost. When we have cost history infor-
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mation for both censored and uncensored observations, we can replace the censored
cost by supplementing what we have observed with the additional accumulated costs
from upstream observations. This RRimp method is mathematically equivalent to the
ZT estimator, and as demonstrated by simulations and examples in Zhao and Tian
(2001), they are generally more efficient than the BT estimator and its equivalent RR
method.
4. Estimating Survival Functions for Costs
In additional to estimating the mean costs, it is often desirable to estimate the sur-
vival function of costs in practice, since the the survival function can provide more
information about the costs, such as the medians, and quartiles, which are more ro-
bust to outliers. Motivated by the idea of the RR algorithm for estimating the mean
costs, we investigate how to use the RR principle to develop survival estimators for
the costs. We show that a naive way of deriving the survival estimator based on the
RR algorithm for the mean cost estimator will result in a biased estimator. Instead
we propose a new redistribute-to-the-right (RRS) algorithm for an estimator of the
survival function of costs (we add “S” to indicate it is a survival estimator), based
on the original idea from Efron (1967) who discovered the algorithm for the survival
time. We will show that it is equivalent to a simple weighted (SW) survival estimator
of costs, whose form was described in the context of estimating the quality adjusted
lifetime by Zhao and Tsiatis (1997). We also attempt to derive a survival estimator
based on the redistribute-to-the-right algorithm that uses cost history information.
We will discuss the advantage and disadvantage of such an estimator.
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4.1. The SW Estimator and Its Equivalent RRS Estimator
Following the idea of Zhao and Tsiatis (1997), a SW estimator for the survival function
of costs can be obtained by
SˆSW (x) =
1
n
n∑
i=1
∆i
Kˆ(Ti)
I(Mi > x). (2.7)
The large sample property of this estimator, such as its consistency and asymptotic
normality can be established similarly, which is omitted here.
To construct an equivalent RR survival estimator, one is tempted to use the re-
placement costs at each censored points, and estimate the survival function for costs
using the following formula:
Sˆnaive(x) =
1
n
n∑
i=1
{∆iI(Mi > x) + (1−∆i)I(MRRi > x)}. (2.8)
Unfortunately, if we use the empirical distribution function shown above to estimate
the survival function for costs, treating the replaced costs as if they were the real
costs, the estimated curve will be biased, although the area under the curve, i.e.,
the estimated mean costs, is unbiased. This will be demonstrated in subsequent
simulation studies.
In order to find an equivalent RRS estimator, we rely on the original idea of
redistribution-to-the-right proposed by Efron (1967), which was used to explain the
Kaplan-Meier estimator for survival time. For each censored subject, since we do not
know the actual costs, we will find the contributions from observations that are larger
than this subject. Specifically, we first sort all subjects according to their observation
times from the smallest (left) to the largest (right). For any tied observations, we
assume the death time occurs a little earlier than the censored time. Consider a cen-
sored observation i whose initial weight is set to be 1. We distribute its weight evenly
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to all the time points to its right. For example, if there are ni such observations, then
each one gets a weight of 1/ni. Next we find the smallest censored observation to
its right, and redistribute its weight again evenly to all the observations to its right.
Repeat this process until we have redistributed the weight of the largest censoring
time. Note that after redistribution the weights are non-zero only at those complete
observations larger than the censored observation i. Denoting the final weight at the
jth complete event time as W
(i)
j , it represents the contribution of a complete subject
j to the censored subject i.
Due to censoring we often cannot evaluate the mark I(Mi > x), instead we use the
weighted sum
I(Mi > x)
RR =
n∑
j=1
∆jI(Tj > Xi)W
(i)
j I(Mj > x) (2.9)
as the replacement mark. As a result, the RRS estimator for the survival function of
costs is
SˆRR(x) =
1
n
n∑
i=1
{∆iI(Mi > x) + (1−∆i)I(Mi > x)RR}. (2.10)
We illustrate this idea using a simple example. Assume we have data [X =
{1, 2, 3, 4, 5},∆ = {1, 0, 1, 0, 1},M = {10, 20, 40, 30, 50}]. As shown in Figure 2, we
first find the weight W
(2)
j , i.e. the contribution of complete observations to the cen-
sored observation 2. In Step 0, the censored observation 2 gets the weight of 1. In
Step 1, we distribute its weight of 1 to all the 3 observations to its right, so that each
of them gets a weight of 1/3. Moving to the next censoring time, observation 4, we
distribute its weight of 1/3 to the one observation to its right, making the weight at
time 5 to be 2/3. Hence we have W
(2)
3 = 1/3, and W
(2)
5 = 2/3.
It is easy to obtain the contributions of complete observations to the censoring
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Figure 2. An example for weight W
(2)
j .
observation 4, in this case, W
(4)
5 =1. Hence the RR
S estimator is
SˆRR(x) =
1
5
5∑
i=1
[∆iI(Mi > x) + (1−∆i)I(Mi > x)RR]
=
1
5
{I(M1 > x) + I(M3 > x) + I(M5 > x) + I(M2 > x)RR + I(M4 > x)RR}
=
1
5
{I(M1 > x) + I(M3 > x) + I(M5 > x)
+
1
3
I(M3 > x) +
2
3
I(M5 > x) + I(M5 > x)}
=
1
5
{I(M1 > x) + 4
3
I(M3 > x) +
8
3
I(M5 > x)}.
The simple weighted estimator for this example is
SˆSW (x) =
1
5
5∑
i=1
[
∆iI(Mi > x)
Kˆ(Ti)
]
=
1
5
{I(M1 > x)
1
+
I(M3 > x)
3/4
+
I(M5 > x)
3/8
}
=
1
5
{I(M1 > x) + 4
3
I(M3 > x) +
8
3
I(M5 > x)}.
It is clear that the RRS estimator is equivalent to the SW survival estimator for costs
in this example.
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Remarks
1. It is not difficult to find that the weight W
(i)
j is related to the estimated con-
ditional probability of an event occurring at Xj given that the subject is alive
at Xi (discrete case). Thus, W
(i)
j can be easily obtained from Kaplan-Meier
estimator:
W
(i)
j =
1
nSˆT (Ci)Kˆ(Tj)
, (2.11)
where SˆT (x) is the Kaplan-Meier estimator for Pr(T > x), Kˆ(x) is the Kaplan-
Meier estimator for Pr(C > x).
2. The weightsW
(i)
j are exactly the weights needed for obtaining the replaced costs
for a censored observation i, in estimating the mean costs, i.e.
MRRi =
n∑
j=1
∆jI(Xj > Xi)W
(i)
j Mj. (2.12)
3. We can show that this RRS estimator (2.10) for the survival function of costs
is mathematically equivalent to the SW estimator based on the similar results
for mean cost estimators.
4.2. RR Improved Survival Estimator for the Survival Function of Costs
As in the case of estimating the mean costs, the SW and its equivalent RRS estimator
for the survival function of costs are not efficient, since they utilize only the costs from
complete observations. Based on the principles of constructing the RRS survival
estimator and the RRimp estimator for mean costs, we propose an improved RR
survival (RRimpS) estimator, as shown below:
SˆRRimp(x) =
1
n
n∑
i=1
[∆iI(Mi > x) + (1−∆i)I(Mi > x)RRimp], (2.13)
17
where
I(Mi > x)
RRimp =
∑
j
[∆jI(Tj > Xi)W
(i)
j I(M
(i)
j > x)], (2.14)
is the new replacement mark, andM
(i)
j =Mi(Ci)+Mj−Mj(Ci) is the cost combining
information from censored and complete data.
This RRimpS estimator is always monotone, which is a desirable property for a
survival estimator. In contrast, an improved survival function estimator of costs
developed similar to Zhao and Tsiatis (1997), which we will call the ZTS survival
estimator, cannot be guaranteed to be monotone (Huang and Louis, 1998). The
RRimpS estimator is also more efficient than the SW estimator and the ZTS estimator,
for many realistic situations. However, unlike the SW and the ZTS estimators, this
RRimpS estimator is not consistent anymore. In the next section, we will conduct
simulation experiments to examine the properties of these survival estimators.
5. Simulation Studies
We conduct simulation studies under several different scenarios to evaluate the sur-
vival function estimators for costs. We generate survival times using an exponential
distribution T ∼ exp(10), and a uniform distribution T ∼ Unif(0, 15). The survival
time is truncated at L=10. We generate also censoring times using a uniform distri-
bution, C ∼ Unif(0, 22), for light (25%-30%), and Unif(0, 15), for heavy censoring
(37%-44%). The sample size is set to be 100, and the number of simulations is 1000.
We consider U-shaped sample paths for the cost distribution, similar to the simu-
lation settings of Bang and Tsiatis (2002) and Zhao et al. (2012). We partition the
entire time period of 10 years into 10 equal intervals. Each individual’s costs consist
of initial diagnostic costs incurred at time 0, terminal costs incurred during the last
year before the failure time, fixed annual costs, and random annual costs (which vary
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from year to year). The diagnostic costs, fixed annual costs, random annual costs,
and terminal costs are generated using a log normal distribution with parameters
(10, 0.2452), (6, 0.2452), (4, 0.2452), (9, 0.6322), respectively. We estimate the survival
function of costs using the SW estimator, the ZTS estimator from Zhao and Tsiatis
(1997), and our RRimpS estimator, under the four different simulation scenarios. We
also examined the naive survival estimator of (2.8) for one of the settings.
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Figure 3. The mean of estimated survival functions for costs from 1000 replications
with naive method.
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Figure 3 shows the true survival function for costs and the average of the survival
curves from the 1000 simulations using different estimators, for the setting with heavy
censoring and exponential survival time. As expected, the SW estimator and the ZTS
estimator are both unbiased since they overlap with the true survival curve. However,
the naive method obtained by using the replacement costs as the true costs is severely
biased. Similar biases for the naive method under other scenarios are also observed.
Figure 4 and Figure 5 display the mean and sample variance of different survival
function estimators for costs based on 1000 replications, under four simulation scenar-
ios. The SW and ZTS estimators are consistent as in Figure 3, since they overlap with
the true survival curve. Although from a theoretical point of view the new proposed
RRimpS estimator is not always consistent, its average survival curves follow the true
survival curves very well, for all the settings considered here. This indicates that the
bias of the RRimpS survival estimator is relatively small. In the plots of the sample
variances, we find that the ZTS estimator is more efficient than the SW estimator.
More importantly, our RRimpS estimator outperforms both SW and ZTS estimators
under all these four scenarios, with more efficiency gain under a heavy censoring.
The results show that the RRimpS survival function has significant improvement in
efficiency. More importantly, the improvement is achieved without sacrificing the
monotonicity property, unlike the ZTS estimator and other more efficient estimators
(Huang and Louis, 1998).
Since the RRimpS survival estimator performs worse when there is a high corre-
lation between costs accumulated in different periods, we design an extreme case to
examine how biased the RRimpS estimator could be. We generate the fixed annual
costs using a log normal distribution with parameters (8, 0.2452), while setting the
diagnostic costs, random annual costs, and terminal costs to be 0. All other pa-
rameters stay the same. The mean survival curves and the Mean Squared Errors
20
0 10000 30000 50000
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
T~exp, light censoring
Cost
Su
rv
iva
l f
un
ct
io
n
True
SW
ZTS
RRimpS
0 10000 30000 50000
0.
2
0.
4
0.
6
0.
8
1.
0
T~exp, heavy censoring
Cost
Su
rv
iva
l f
un
ct
io
n
True
SW
ZTS
RRimpS
0 10000 30000 50000
0.
2
0.
4
0.
6
0.
8
1.
0
T~unif, light censoring
Cost
Su
rv
iva
l f
un
ct
io
n
True
SW
ZTS
RRimpS
0 10000 30000 50000
0.
2
0.
4
0.
6
0.
8
1.
0
T~unif, heavy censoring
Cost
Su
rv
iva
l f
un
ct
io
n
True
SW
ZTS
RRimpS
Figure 4. The mean of estimated survival functions for costs from 1000 replications.
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Figure 5. The sample variance of estimated survival functions for costs from 1000
replications.
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Figure 6. The mean and MSE of estimated survival functions for costs under the
extreme case from 1000 replications.
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(MSE=variance+bias2), for the case with exponential survival time and heavy cen-
soring, and for different sample sizes (n=100, 400), are displayed in Figure 6. We
observe similar trends for other simulation settings. Figure 6 shows that the bias for
the RRimpS estimator is noticeable now, albeit very small. The MSE for the RRimpS
estimator is still mostly the smallest among the three methods available, even when
the sample size is as large as 400. In general, as the sample size gets larger, the
variance becomes smaller but the bias stays the same, we expect the gain in terms of
MSE for the RRimpS estimator will decrease with increasing sample sizes.
6. Conclusion
In this chapter we extend the research conducted by Zhao et al. (2011) who provided a
link between a theoretically justified mean cost estimator which is based on the inverse
probability weighting techniques, the BT estimator, and an intuitive RR estimator.
We propose a modified replace-from-the-right algorithm, the RRimp estimator, which
utilizes the cost history process and therefore is generally more efficient than the RR
estimator. We establish a mathematical equivalency between the RRimp estimator
and an improved mean cost estimator, the ZT estimator. Thus, we are able to provide
an intuitive explanation on how the ZT estimator works. We believe our effort enables
a better understanding of the theoretically derived mean cost estimators, the BT and
ZT estimators, and meanwhile provides justification for the simple, intuition based RR
and RRimp estimators. Due to a lack of a theoretical background for understanding
the BT and ZT estimators, some practitioners might be reluctant to use them. With
the easy interpretation of the RR and RRimp estimators, and established equivalency
between these estimators and the BT, ZT estimators, we believe these estimators will
become more popular among practitioners.
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It proves to be a more challenging problem deriving an intuitive estimator for the
survival function of costs. We show that a naive method using the replaced cost as the
true costs in an empirical survival function gives rise to a biased estimator. Resorting
to the original idea of redistribute-to-the right algorithm (Efron, 1967) for explaining
the Kaplan-Meier estimator, we construct a RRS survival estimator, which can be
shown to be equivalent to the SW survival estimator for costs. We also propose a
RRimpS survival estimator which has the desirable property of being monotone, and
more efficient than the RRS survival estimator, but unfortunately, this estimator is
not always consistent. Since the bias seems to be quite small from many simulations
we conduct, it may be considered as an alternative survival estimator for costs in
a real setting when the sample size is not very large and cost history information is
available. Further research needs to be conducted in order to find a survival estimator
for costs which is monotone, consistent and efficient.
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CHAPTER III
ESTIMATING ICER AND CI WITH DIFFERENT TERMINATING
EVENTS FOR SURVIVAL TIME AND COSTS
1. Introduction
Due to skyrocketing costs of health care and limited resources available, economic
studies of different treatment options are becoming increasingly popular in evaluating
new treatment strategies. The U.S. Preventive Services Task Force and the Panel of
Cost-Effectiveness in Health and Medicine have urged consideration of both cost and
clinical effectiveness when directing health care investments. They have also issued
a comprehensive set of guidelines to aid practitioners of Cost-effectiveness Analysis
(CEA) (Gold et al., 1996; Walker, 2001; American College Physicians, 2008). It is
clear that if two competing programs do not differ in their health benefits, then
the one with the lower cost would be preferred. On the other hand, if the costs of
two programs are judged equivalent, the intervention with the greater health benefit
would be preferred. However, when a program has both higher cost and greater
benefit than its competitor, a decision must be made as to which of the two programs
should be adopted. The incremental cost-effectiveness ratio (ICER) is designed to
measure the trade-off between the costs and health benefits of medical interventions.
It is defined as the costs incurred for saving an additional year of life. This measure
has been the most popular tool used for CEA (e.g., Zwanziger et al., 2006; Wailoo
et al., 2008; McIntosh et al., 2009; Edlin et al., 2010; Huang et al., 2010; Maud et al.,
2010; Shiroiwa et al., 2010; Linde et al., 2011).
The analysis of cost data involves some unique challenges that require advanced sta-
tistical methodologies, especially when costs are censored. For example, randomized
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clinical trials often enroll subjects over a broad time period, but the trial ends at a
fixed time point. As a result, subjects are observed for differing amounts of time, and
those who are still alive at the end of the study are considered censored. It has been
just over a decade since it was recognized that caution should be exercised regarding
the non-standard survivorship bias inherent in censored cost data, as described in a
landmark paper by Lin et al. (1997). The authors pointed out that censored cost
data can be problematic when analyzed using most standard tools, including sample
mean and variance, t-test, ordinary least squares, Kaplan-Meier estimator, Log-rank
test, and Cox proportional hazards regression. The problem arises from the induced
informative censoring problem. Even when the survival time and the censoring time
are independent, which is true for end-of-study or administrative censoring in clinical
trials, the corresponding costs are generally not independent. Major efforts have been
made to provide consistent and efficient estimation of mean medical costs (Bang and
Tsiatis, 2000; Zhao and Tian, 2001; Bang, 2005; Zhao et al., 2007, among others).
Since ICER is a ratio statistics, the distribution of ICER is quite skewed. Thus,
instead of providing the standard errors of the ICER, it is often desirable to construct
a confidence interval (CI) for the ICER in order to estimate its variability. Various
methods have been proposed on finding CIs for the ICER. Non parametric bootstrap-
ping methods include Efron and Tibshirani (1986); Efron and Tibshirani (1993); Cook
and Heyse (2000); Jiang and Zhou (2004); Dinh and Zhou (2006); Wang and Zhao
(2008), and parametric methods include Fieller (1954); O’Brien et al. (1994); Laska
et al. (1997); Gardiner et al. (2001). Although most researchers believe that the
bootstrap method provides better coverage, since the Fieller method is based on the
large sample normal assumption, Hwang (1995) and Jiang et al. (2000) showed that
both of them are equivalent since they are both first order accurate.
To estimate ICER and calculate its confidence intervals by Fieller’s theorem, we
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need estimate not only between-treatment differences with respect to cost and effect,
but also their respective variances and covariance. Many researchers have proposed
methods for estimating the mean medical costs and related variance, and most of them
focus on the restricted medical costs, i.e., the costs accumulated within a time limit.
A challenge comes when the terminating events for cost and survival are different.
For example, a new strategy might prevent the heart failure event, but may not
improve the overall survival time. Hence, it extends the heart failure free survival
time, but not the overall survival time. Meanwhile, we are still interested in the cost
estimation up to death. Although the construction for the CI of usual ICER with the
same terminating points has been studied much, there are no theoretical results for
research on the ICER and its CI which allow different terminating events.
The remainder of this chapter is organized as follows. We first review mean cost and
mean survival estimator, as well as their variance estimators, and propose the modified
form for mean heart failure free survival estimator. A consistent estimator for ICER
with different terminating events will then be proposed, as well as the construction
method of corresponding CI. As one of key steps, the covariance estimator between
mean cost and heart failure free survival estimators are proposed together. This is
followed by the numerical studies, which displays the performance of our proposed
covariance formula, as well as the empirical coverage of CI for this special ICER.
Finally, the application for this method and our future works will be discussed.
2. Method
2.1. Notation and Assumptions
For clinical trials, the death of patients may not be observed until study ends. There-
fore, those patients are treated as censored subjects, with their survival time and
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total costs unknown.
Moreover, assume the patients in study may suffer from heart failure, and a new
treatment can reduce the risk of heart failure. Thus, patients with the new treatment
tend to have longer time before heart failures, or even they may have no heart failures
occurred during overall survival time. Therefore, we define heart failure free survival
time as the time of heart failure or death, whichever occurs first. Since the new
treatment can lower the risk of heart failure, but not extend the overall survival
time, this heart failure free survival time can measure the effects of the treatment
better. Meanwhile, the cost cumulation is until the overall survival time. Thus, there
will be four types of patients: observing death without heart failure; observing heart
failure first and then death; observing heart failure and then censored; censored before
observing death or heart failure.
We first concentrate on patients in one arm of the study. For the ith person, let
Ti denote the overall survival time, T
F
i denote the heart failure free survival time,
i.e. T Fi = min(HFi, Ti), where HFi is the time when a patient has a heart failure.
Ci is the censoring time. Denote overall follow-up time Xi = min(Ti, Ci), and death
indicator ∆i = I(Ti ≤ Ci). Similarly, XFi = min(T Fi , Ci),∆Fi = I(T Fi ≤ Ci), where
I(.) is the indicator function. Let Mi(u) be the cost accumulated over time u. For
simplicity, we denote Mi =Mi(Xi) as the observed total cost.
We assume that the censoring times Ci is independent of the survival time Ti,
the heart failure time HFi, and the cost history process {Mi(u), u ≤ Ti}. This
assumption is reasonable for a well conducted clinical trial, where censoring is mainly
caused by different entering times into the study, and cost collection is ended early
due to reasons other than patients’ health status. Due to the presence of censoring,
it is impossible to estimate the cost over the entire health history. Therefore, we only
consider cost accumulated up to a maximum of L units of time. This is equivalent to
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redefining our survival time as TLi = min(Ti, L), and T
FL
i = min(T
F
i , L). For ease of
notation, we suppress the superscript L of TLi and T
FL
i later.
For each of the two treatment groups, k = 0, 1, we observe the following identi-
cally distributed, independent data {Xi,∆i, XFi ,∆Fi ,Mi(Xi), i = 1, · · · , nk}; nk is the
number of patients for arm k. Our goal is to estimate the mean cost µM = E(Mi)
and the mean heart failure free survival time µF = E(T Fi ) for each of the treatment
groups, and then obtain the ICER and its confidence interval comparing the two
treatment groups.
2.2. Estimating Mean Cost for Each Group
For estimation of mean cost accumulated over time L with censoring data, a consistent
estimator was proposed by Bang and Tsiatis (2000) based on the inverse probability
weighting technique:
µˆMBT =
1
n
n∑
i=1
∆iMi
Kˆ(Ti)
, (3.1)
where Mi is the total observed cost for the ith individual, and Kˆ(Ti) is the Kaplan-
Meier estimator for the survival function of the censoring time, K(u) = Pr(Ci >
u). K(Ti) represents the probability that a subject is uncensored at Ti. The basic
idea of this estimator is that each complete observation represents potential 1/Kˆ(Ti)
observations who might be censored.
When cost history is available, the BT estimator is not efficient since it does not
use the cost information from censored ones. A more efficient estimator is proposed
by Zhao and Tian (2001). We can estimate the mean cost by using their improved
estimator:
µ̂MZT = n
−1
n∑
i=1
∆iMi
K̂(Ti)
+ n−1
n∑
i=1
∫ L dNCi (u)
K̂(u)
[Mi(u)− Ĝ∗{M(u), u}], (3.2)
30
where K̂(u) is the Kaplan-Meier estimator for survival distribution of Ci at time u,
NC(u) =
n∑
i=1
NCi (u) =
n∑
i=1
I(Xi ≤ u,∆i = 0),
Ĝ∗{M(u), u} = {
n∑
i=1
Mi(u)Yi(u)}/Y (u), (3.3)
and Y (u) =
∑n
i=1 Yi(u) =
∑n
i=1 I(Xi ≥ u).
The ZT estimator has the following simplified form (Pfeifer and Bang, 2005):
µˆMZT =
1
n
n∑
i=1
∆iMi
Kˆ(Ti)
+
1
n
n∑
i=1
(1−∆i)[Mi(Ci)−M(Ci)]
Kˆ(Ci)
, (3.4)
where M(Ci) =
∑n
j=1 I(Xj ≥ Ci)Mj(Ci)/
∑n
j=1 I(Xj ≥ Ci), which is the average
accumulative cost at time Ci of those subjects who are alive at Ci.
It was shown that this estimator is consistent, and asymptotically normally dis-
tributed with variance that can be estimated consistently by
V̂ ar(µ̂MZT ) =
1
n2
n∑
i=1
∆i(Mi − µ̂MZT )2
K̂(Ti)
+
1
n2
∫ L
0
dNC(u)
K̂(u)2
{Ĝ(M2, u)− Ĝ(M,u)2}
− 2
n2
∫ L
0
dNC(u)
K̂(u)2
[Ĝ{MM(u), u} − Ĝ(M,u)Ĝ{M(u), u}]
+
1
n2
∫ L
0
dNC(u)
K̂(u)2
[Ĝ∗{M(u)2, u} − Ĝ∗{M(u), u}2], (3.5)
where
Ĝ(Z, u) =
1
nŜ(u)
n∑
i=1
∆i
K̂(Ti)
ZiI(Ti ≥ u), (3.6)
for any random variable Z, and Ŝ(u) is the Kaplan-Meier estimator for S(u), the
survival distribution of T at time u, using data (Xi,∆i, i = 1, · · · , n).
Ĝ∗{Z, u} = {
n∑
i=1
ZiYi(u)}/Y (u), (3.7)
and Y (u) =
∑n
i=1 Yi(u) =
∑n
i=1 I(Xi ≥ u).
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This formula for variance, given by Zhao and Tian (2001); Zhao and Wang (2010),
is a simplified form of original formula.
2.3. Estimating Mean Heart Failure Free Survival Time for Each Group
The mean survival time can be obtained by the area under the survival function, i.e.,
µ̂T =
∫ L
0
Sˆ(x)dx, (3.8)
where Sˆ(x) is the Kaplan-Meier estimator for S(u) = Pr(T > u). This mean survival
time estimator can be equivalently estimated by (Satten and Datta, 2001):
µ̂T =
1
n
n∑
i=1
∆iTi
K̂(Ti)
. (3.9)
Similarly, the mean heart failure free survival time can be estimated by
µ̂F =
1
n
n∑
i=1
∆Fi T
F
i
K̂F (T Fi )
, (3.10)
where K̂F (u) is the Kaplan-Meier estimator for K(u) = Pr(C > u), the survival
distribution of C at time u, using data (XFi ,∆
F
i , i = 1, · · · , n). Following Zhao and
Tian (2001), its variance can be estimated consistently by
1
n2
n∑
i=1
∆Fi (T
F
i − µ̂F )2
K̂F (Ti)
+
1
n2
∫ L
0
dNF (u)
K̂F (u)2
{ĜF (T F2, u)− ĜF (T F , u)2},(3.11)
where
NF (u) =
n∑
i=1
NCFi (u) =
n∑
i=1
I(XFi ≤ u,∆Fi = 0),
ĜF (Z, u) =
1
nŜF (u)
n∑
i=1
∆Fi
K̂F (T Fi )
ZiI(T
F
i ≥ u), (3.12)
ŜF (u) is the Kaplan-Meier estimator for SF (u) = Pr(T Fi > u).
As discussed in Zhao and Tian (2001), discounting of future years of survival time
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and costs at a specific annual rate can be easily accommodated in the above formulae.
2.4. Estimating the ICER and Its Confidence Interval
To compare two treatments, the ICER is the ratio between difference of their costs
and difference of effects. Here we use mean of heart failure free survival time as the
measure of effectiveness.
For a two-arm trial (k, k = 0, 1), denote µMk as the mean cost and µ
F
k as the mean
heart failure Free survival time, each limited to a window of time [0, L]. We consider
the ICER as the additional cost for a new treatment for saving one year of heart
failure free lifetime and define it as
γ =
µM1 − µM0
µF1 − µF0
,
which can be estimated by
γ̂ =
µ̂M1 − µ̂M0
µ̂F1 − µ̂F0
, (3.13)
where, µ̂Mk is the ZT estimator for the mean cost and µ̂
F
k is the estimator for mean
heart failure free life time for group k.
We use Fieller’s Theorem to obtain confidence intervals for the ICER, similarly as in
Zhao and Tian (2001). Assuming that asymptotically x = µ̂M1 − µ̂M0 and y = µ̂F1 − µ̂F0
are bivariate normally distributed, the 100(1− 2α) percent confidence limits for the
ICER γ are
xy − z2αsxy ± {(xy − z2αsxy)2 − (x2 − z2αsxx)(y2 − z2αsyy)}1/2
y2 − z2αsyy
, (3.14)
where sxx, syy, sxy are respectively the variances of x and y, and the covariance of x
and y, zα is the cut-off point with tail area α of the standard normal distribution. If
the denominator of equation (3.14) is positive, the CI is finite. When the denomina-
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tor is negative, which means the difference between effects of two treatments is not
significant (i.e., zero belongs to the CI of the divisor), the CI for ICER is exclusive
and thus infinite.
The variance of x and y can be obtained from results mentioned earlier, assuming
independent samples. To find the covariance between x and y, we need to find the
covariance between µ̂Mk and µ̂
F
k . The mean heart failure free survival time estimator
and the mean cost estimators can both be described by martingale forms (Zhao and
Tian, 2001), and the covariance between them can be derived based on the counting
process and the general theory for missing data process (Fleming and Harrington,
1991; Robins and Rotnitzky, 1992; Robins et al., 1994). In Appendix B we show that
the covariance between the improved estimator for cost and the estimator for mean
heart failure free survival time for each arm can be estimated consistently by
1
n2
n∑
i=1
∆iMiT
F
i
K̂(Ti)
− 1
n3
n∑
i=1
∆iMi
K̂(Ti)
n∑
i=1
∆Fi T
F
i
K̂F (T Fi )
+
1
n2
∫ L
0
dNCF (u)
K̂F (u)2
{ĜF0(T FM,u)− ĜF0(M,u)ĜF0(T F , u)}
− 1
n2
∫ L
0
dNCF (u)
K̂F (u)2
{ĜF0{T FM(u), u} − ĜF0{M(u), u}ĜF0(T F , u)},
where
ĜF0(Z, u) =
1
nŜF (u)
n∑
i=1
∆i
K̂(Ti)
ZiI(T
F
i ≥ u), (3.15)
As mentioned before, the bootstrap methods can also be used for CI construction,
but they take more time, and not necessarily better than the Fieller’s method, which
can also be seen from the numerical comparison conducted by Wang and Zhao (2008).
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3. Numerical Studies
As commonly used in scenarios for simulation, survival time is simulated by expo-
nential distribution. The overall survival time T ∼ exp(10) for both two groups
with different treatments. The heart failure time HF ∼ exp(6) for Group 0, and
HF ∼ exp(12) for Group 1 with a more effective treatment to prevent heart failure.
T and HF are simulated independently and truncated at L=10, and heart failure free
survival time is T F = min(T,HF ). The censoring time C ∼ Unif(0, 15) with 42%
heavy censoring for overall survival time and 24%-30% censoring rate for heart failure
free survival time. The true mean heart failure free survival time for Group 0 and
Group 1 are 3.49 and 4.58 respectively. Figure 7 shows the survival functions of T F
for two groups. The survival function of Group 1 is above Group 0, which indicates
the patients in Group 1 tend to have a larger heart failure free survival time.
U-shaped sample paths for the costs are considered. The entire time period [0, 10]
is partitioned into 10 equal intervals. There are initial diagnostic cost at time 0, and
terminal cost during the last year before death. Within each time interval, there are
fixed annual cost (which fixes for each patient) and random annual cost (which varies
from year to year). We considered two settings of scenarios with uniform costs and
log normal costs. For uniform setting, the diagnostic cost, fixed annual cost, random
annual cost, and terminal cost are uniform distribution with respective parameters
(1000, 3000), (1000, 2600), (0, 400), (10000, 20000) for Group 0, and (20000, 30000),
(1000, 1600), (0, 400), (10000, 20000) for Group 1. For log normal setting, the diag-
nostic cost, fixed annual cost, random annual cost, and terminal cost are log nor-
mal distribution with respective parameters (9, 0.2452), (6.5, 0.2452), (4, 0.2452), and
(9, 0.6322) for Group 0, and (10, 0.2452), (6, 0.2452), (4, 0.2452), and (9, 0.6322) for
Group 1. The true mean cost for Group 0 and Group 1 are 23646 and 43505 under
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Figure 7. The survival functions of heart failure free survival time for two groups.
uniform setting, and 18998 and 31651 under log normal setting. Thus, the more
effective treatment adopted by Group 1 saves more heart failure free lifetime, while
costs much more than Group 0 by a large amount of diagnostic cost. Figure 8 shows
the kernel densities of costs for two groups, which indicates the mean cost of Group
1 is more than Group 0. It can also be seen that the distribution of log normal costs
is more skew than the uniform costs.
The simulation results for variance and covariance estimation based on 2000 replica-
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Figure 8. The kernel densities of cost for two groups in simulation.
tions are summarized in Table 1, where SVar is the sample variance of the estimator,
EVar is the mean of estimated variance, SCov is the sample covariance of µˆM and µˆF ,
and ECov is the mean of estimated covariance. The results show that the estimated
variance and covariance are close to the sample variance and sample covariance, and
the biases of estimators are small. Thus, the simulations display the consistency of
those estimators. The empirical coverage under different scenarios are shown in Table
2, in which we can find the coverage is approaching to nominal level as the sample
size increases.
4. Conclusion
Censoring brings challenges to estimating ICER and calculating its CI in cost-effectiveness
analysis, since usually failures can not be observed for all patients during clinical tri-
als. Another new challenge comes from the different terminating events, which is
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Table 1
Summary of variance and covariance estimation from 2000 replications
µˆM µˆF Cov(µˆM , µˆF )
Cost n k Bias SVar EVar Bias SVar EVar SCov ECov
Lnorm 100 0 19 770464 772142 -0.014 0.118 0.106 9.4 13.3
1 -30 1072544 1063645 0.005 0.145 0.141 -24.2 -23.7
200 0 20 385962 389229 -0.003 0.055 0.053 2.0 2.9
1 -28 525137 532257 -0.005 0.070 0.071 -11.8 -13.0
400 0 15 196160 195746 -0.003 0.026 0.026 1.1 1.5
1 11 264317 266563 -0.008 0.036 0.035 -7.3 -6.9
Unif 100 0 18 933790 895854 -0.016 0.116 0.106 69.2 75.4
1 21 778935 768607 -0.011 0.148 0.140 44.1 42.3
200 0 -20 438629 444898 0.006 0.052 0.053 31.8 34.5
1 22 372260 384993 0.005 0.068 0.070 18.1 19.1
400 0 -17 214646 222930 0.003 0.026 0.027 17.7 16.9
1 6 191395 192043 0.004 0.035 0.035 8.0 8.7
commonly encountered when the treatment aims to low risk of some events, for in-
stance, heart failure in our article, but not the extension of the overall survival time.
Therefore, statistical inference for ICER allowing different terminating events are
needed for practitioners to evaluate such a new treatment.
In this chapter, we provide a consistent estimator for ICER with different termi-
nating events, as well as a method to construct its CI. Our method not only handles
censoring problem well, but also allows different terminal events. Simulation studies
showed that our covariance estimator and the constructed CI perform very well for
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Table 2
Empirical coverage of confidence intervals for ICER from 2000 replications
Sample Nominal Log normal Uniform
Size level Cost Cost
100 0.95 0.935 0.936
0.90 0.884 0.879
0.80 0.781 0.779
200 0.95 0.948 0.945
0.90 0.895 0.899
0.80 0.801 0.798
400 0.95 0.953 0.954
0.90 0.908 0.902
0.80 0.803 0.793
some practical settings. Thus, our method provides an effective way to make statis-
tical inference for such data and is easy to implement. Furthermore, our proposed
covariance estimator can be used not only in the construction of CI for ICER, but
also other cases which require the covariance estimator.
Further work may be conducted to compare our method with Bootstrap method,
and investigate how ICER changes with different groups. Besides, ICER with heart
failure Free Quality-Adjusted lifetime (QAL) can also be studied similarly.
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CHAPTER IV
SUMMARY
In this thesis, several innovative methods are proposed for cost estimation and cost-
effectiveness analysis with censored data. Censoring brings unique challenges to this
field, since we cannot observe complete data for all the subjects in the study. Even
though it is reasonable to assume that the censoring and the potential event time are
independent (or conditionally independent) for most studies, the “induced informative
censoring” problem makes the cost evaluation more difficult, since many standard
methods for survival analysis are not appropriate for cost evaluation any more.
We first extend the research conducted by Zhao et al. (2011) who provided a link be-
tween the BT estimator and an intuitive RR estimator for estimating mean costs with
censored data. Our proposed RRimp estimator utilizes the cost history and therefore
is generally more efficient than the RR estimator. We establish the mathematical
equivalency between the RRimp estimator and an improved mean cost estimator, the
ZT estimator. Thus, we are able to provide an intuitive explanation for how the ZT
estimator works. We believe our effort enables a better understanding of the theo-
retically derived mean cost estimators, the BT and ZT estimators, and meanwhile
provides justification for the simple, intuition based RR and RRimp estimators.
It is more challenging to derive an intuitive estimator for the survival function of
costs. Motivated by the original idea of redistribute-to-the right algorithm (Efron,
1967) for explaining the Kaplan-Meier estimator, we construct a RRS survival esti-
mator, which can be shown to be equivalent to the SW survival estimator for costs.
We also propose a RRimpS survival estimator which has the desirable property of
being monotone, and more efficient than the RRS survival estimator, but unfortu-
nately, this estimator is not always consistent. Since the bias seems to be quite small
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from many simulations we conduct, it may be considered as an alternative survival
estimator for costs in a real setting when the sample size is not very large and cost
history information is available. Further research needs to be conducted in order to
find a survival estimator for costs which is monotone, consistent and efficient.
In performing cost-effectiveness analysis with censored data, a new challenge arises
from having the different terminating events for survival and cost estimation. There-
fore, statistical inference for ICER allowing different terminating events is desirable
for practitioners to deal with such data. We propose a consistent estimator for this
special ICER, as well as a method to construct its CI. The conducted simulation
studies show that our method performs very well for some practical settings. Thus,
our method provides an effective way to make statistical inference for such data and is
easy to implement. Further work for ICER and corresponding CI may be conducted to
compare our method with the Bootstrap method, and investigate how ICER changes
with different groups.
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APPENDIX A
PROOF FOR THE EQUIVALENCY OF THE ZT MEAN COST
ESTIMATOR AND THE RRIMP METHOD
Suppose we have observed the following survival and cost history data
[{Xi,∆i,Mi,Mi(tj), j = 1, · · · , J}, i = 1, · · · , n],
where i denotes individuals, tj(j = 1, · · · , J) denotes the ordered distinctive censoring
times. Let Yj indicate the number of people who have observation times greater than
tj (i.e., Yj =
∑n
i=1 I(Xi > tj)), and nj represent the number of people who are
censored at time tj. If an event occurs at a censoring time tj, we assume this event
happens shortly before tj. Therefore, the set {Xi = tj} consist only of censored data.
First, for the subject i who is censored at tj (note that we allow multiple subjects
who are censored at time tj), define δMi(tj) as the difference between the observed
cost at time tj for the ith subject and the average accumulated cost at tj for subjects
who are still alive at tj:
δMi(tj) =Mi(tj)−M(tj) =Mi(tj)−
∑
i:Xi≥tj Mi(tj)
Yj + nj
. (A.1)
Define M∗(tj) as the sum of δMi(tj) over all subjects who are censored at tj:
M∗(tj) =
∑
i:Xi=tj
δMi(tj) =
∑
i:Xi=tj
Mi(tj)− njM(tj)
=
∑
i:Xi=tj
Mi(tj)− nj
Yj + nj
∑
i:Xi≥tj
Mi(tj). (A.2)
Starting from the largest censoring time tJ , there are YJ subjects who have complete
costs and whose survival times are greater than tJ . Hence, the RRimp cost for the
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kth subject censored at tJ is
MRRimpJ,k =Mk(tJ) +
1
YJ
∑
i:Xi>tJ
{Mi −Mi(tJ)}.
Recall that the replacement cost from RR method for the kth subject censored at
time tJ is
MRRJ =
1
YJ
∑
i:Xi>tJ
Mi,
thus, the sum of difference between MRRimpJ,k (in RRimp method) and M
RR
J (in RR
method) at tJ is
∑
k:Xk=tJ
(MRRimpJ,k −MRRJ )
=
∑
k:Xk=tJ
Mk(tJ) +
nJ
YJ
∑
i:Xi>tJ
{Mi −Mi(tJ)} − nJ
YJ
∑
i:Xi>tJ
Mi
=
∑
i:Xi=tJ
Mi(tJ)− nJ
YJ
∑
i:Xi>tJ
Mi(tJ)
= (1 +
nJ
YJ
)
∑
i:Xi=tJ
Mi(tJ)− nJ
YJ
∑
i:Xi≥tJ
Mi(tJ)
= (1 +
nJ
YJ
){
∑
i:Xi=tJ
Mi(tJ)− nJ
YJ + nJ
∑
i:Xi≥tJ
Mi(tJ)}
= (1 +
nJ
YJ
)M∗(tJ). (A.3)
Now we move to the 2nd largest censoring time tJ−1, where the number of subjects
surviving longer than tJ−1 is YJ−1. The RRimp cost for the kth censored subject at
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tJ−1 is
MRRimpJ−1,k
= Mk(tJ−1) +
1
YJ−1
∑
i:Xi>tJ−1
{Mi −Mi(tJ−1)}
= Mk(tJ−1) +
1
YJ−1
{
∑
i:Xi>tJ−1
∆i[Mi −Mi(tJ−1)] +
∑
i:Xi=tJ
[MRRimpJ,i −Mi(tJ−1)]}
= Mk(tJ−1) +
1
YJ−1
{
∑
i:Xi>tJ−1
∆iMi −
∑
i:Xi>tJ−1
∆iMi(tJ−1)−
∑
i:Xi=tJ
Mi(tJ−1)
+
∑
i:Xi=tJ
Mi(tJ) +
nJ
YJ
∑
i:Xi>tJ
∆i[Mi −Mi(tJ)]}
= Mk(tJ−1) +
1
YJ−1
{
∑
i:Xi>tJ
∆iMi +
∑
i:tJ−1<Xi≤tJ
∆iMi −
∑
i:Xi>tJ−1
Mi(tJ−1)
+
∑
i:Xi=tJ
Mi(tJ) +
nJ
YJ
∑
i:Xi>tJ
∆iMi − nJ
YJ
∑
i:Xi>tJ
Mi(tJ)}
=
1
YJ−1
(1 +
nJ
YJ
)
∑
i:Xi>tJ
∆iMi +
1
YJ−1
∑
i:tJ−1<Xi≤tJ
∆iMi +Mk(tJ−1)
− 1
YJ−1
∑
i:Xi>tJ−1
Mi(tJ−1) +
1
YJ−1
∑
i:Xi=tJ
Mi(tJ)− nJ
YJYJ−1
∑
i:Xi>tJ
Mi(tJ)
where the first two terms 1
YJ−1
(1 + nJ
YJ
)
∑
i:Xi>tJ
∆iMi +
1
YJ−1
∑
i:tJ−1<Xi≤tJ ∆iMi =
MRRJ−1 (Zhao et al. 2011). Thus, the sum of difference between M
RRimp
J−1,k and M
RR
J−1 at
50
tJ−1 is
∑
k:Xk=tJ−1
(MRRimpJ−1,k −MRRJ−1)
=
∑
i:Xi=tJ−1
Mi(tJ−1)− nJ−1
YJ−1
∑
i:Xi>tJ−1
Mi(tJ−1) +
nJ−1
YJ−1
∑
i:Xi=tJ
Mi(tJ)
−nJ−1nJ
YJ−1YJ
∑
i:Xi>tJ
Mi(tJ)
= (1 +
nJ−1
YJ−1
)
∑
i:Xi=tJ−1
Mi(tJ−1)− nJ−1
YJ−1
∑
i:Xi≥tJ−1
Mi(tJ−1)
+
nJ−1
YJ−1
(1 +
nJ
YJ
)
∑
i:Xi=tJ
Mi(tJ)− nJ−1nJ
YJ−1YJ
∑
i:Xi≥tJ
Mi(tJ)
= (1 +
nJ−1
YJ−1
)M∗(tJ−1) +
nJ−1
YJ−1
(1 +
nJ
YJ
)M∗(tJ) (A.4)
Similarly, we have
∑
k:Xk=tJ−2
(MRRimpJ−2,k −MRRJ−2)
= (1 +
nJ−2
YJ−2
)M∗(tJ−2) +
nJ−2
YJ−2
(1 +
nJ−1
YJ−1
)M∗(tJ−1)
+
nJ−2
YJ−2
(1 +
nJ−1
YJ−1
)(1 +
nJ
YJ
)M∗(tJ) (A.5)
In (A.3), the contribution of M∗(tj) is (1 + nJYJ ). In (A.4), its contribution is
nJ−1
YJ−1
(1 + nJ
YJ
). For (A.5), the contribution is nJ−2
YJ−2
(1 + nJ−1
YJ−1
)(1 + nJ
YJ
). If we generalize
the conclusion and sum up the equations from J to 1, we can find the contribution of
M∗(tJ) is(
1 +
nJ
YJ
)
+
(
1 +
nJ
YJ
)
· nJ−1
YJ−1
+ · · ·+
(
1 +
nJ
YJ
)
· · ·
(
1 +
n2
Y2
)
· n1
Y1
=
J∏
j=1
(
1 +
nj
Yj
)
.
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Similarly, the contribution of M∗(tj) is(
1 +
nj
Yj
)
+
(
1 +
nj
Yj
)
· nj−1
Yj−1
+ · · ·+
(
1 +
nj
Yj
)
· · ·
(
1 +
n2
Y2
)
· n1
Y1
=
j∏
l=1
(
1 +
nl
Yl
)
.
Hence,
µˆRRimp
=
1
n
{
n∑
i=1
∆iMi +
∑
k:Xk=tJ
MRRimpJ,k +
∑
k:Xk=tJ−1
MRRimpJ−1,k + · · ·+
∑
k:Xk=t1
MRRimp1,k }
=
1
n
{
n∑
i=1
∆iMi +
∑
k:Xk=tJ
MRRJ +
∑
k:Xk=tJ−1
MRRJ−1 + · · ·+
∑
k:Xk=t1
MRR1 }
+
1
n
{
J∏
j=1
(1 +
nj
Yj
)M∗(tJ) +
J−1∏
j=1
(1 +
nj
Yj
)M∗(tJ−1) + · · ·+ (1 + n1
Y1
)M∗(t1)}
= µˆRR +
1
n
{
J∏
j=1
(1 +
nj
Yj
)M∗(tJ) +
J−1∏
j=1
(1 +
nj
Yj
)M∗(tJ−1) + · · ·+ (1 + n1
Y1
)M∗(t1)}
Where µˆRR = µˆBT is already known, andM
∗(tj) =
∑
i:Xi=tj
[Mi(tj)−M(tj)] according
to its definition. It can also be shown that the Kaplan-Meier estimator for K(tj) is
Kˆ(tj) =
j∏
l=1
Yl
Yl + nl
,
which means
1
Kˆ(tj)
=
1∏j
l=1
Yl
Yl+nl
=
j∏
l=1
(
1 +
nl
Yl
)
.
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Thus,
µˆRRimp
= µˆBT +
1
n
{
∑
i:Xi=tJ
[Mi(tJ)−M(tJ)]
Kˆ(tJ)
+
∑
i:Xi=tJ−1 [Mi(tJ−1)−M(tJ−1)]
Kˆ(tJ−1)
+
∑
i:Xi=tJ−2 [Mi(tJ−2)−M(tJ−2)]
Kˆ(tJ−2)
+ · · ·+
∑
i:Xi=t1
[Mi(t1)−M(t1)]
Kˆ(t1)
}
= µˆBT +
1
n
n∑
i=1
(1−∆i)[Mi −M(Ci)]
Kˆ(Ci)
= µˆZT .
We have proved that the RRimp estimator is the same as the ZT estimator for
estimating the mean cost.
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APPENDIX B
ESTIMATING THE COVARIANCE BETWEEN THE MEAN COST
AND THE MEAN HEART FAILURE FREE SURVIVAL TIME
For ease of notation, we confine our attention to one arm of the study. We define two
martingales based on the censoring variable for the survival time and heart failure free
survival time, Ti and T
F
i , respectively. For the ith individual, the martingale for the
censoring variable for survival time Ti is defined asM
C
i (u) = N
C
i (u)−
∫ u
0
λC(t)Yi(t)dt,
where λC(u) is the hazard function for C, λC(u) = limh→0 1h Pr(C < u + h|C ≥ u),
Yi(u) = I(Xi ≥ u), NCi (u) = I(Xi ≤ u,∆i = 0). Similarly, the martingale for the
censoring variable for heart failure free survival T Fi is defined asM
CF
i (u) = N
CF
i (u)−∫ u
0
λC(t)Y Fi (t)dt, where Y
F
i (u) = I(X
F
i ≥ u), NCFi (u) = I(XFi ≤ u,∆Fi = 0). The
filtration F(u) is defined as the increasing sequence of σ−algebras generated by
σ{I(Ci ≤ x), x ≤ u; I(Ti ≤ s), I(T Fi ≤ s),Mi(s), 0 ≤ s <∞, i = 1, . . . , n}.
Using results from Zhao and Tian (2001), the improved cost estimator can be
expressed approximately by
n
1
2 (µ̂M − µM)
= n−
1
2
n∑
i=1
(Mi − µM)− n− 12
n∑
i=1
∫ L
0
dMCi (u)
K(u)
{Mi −G(M,u)}
+n−
1
2
n∑
i=1
∫ L
0
dMCi (u)
K(u)
[Mi(u)−G{M(u), u}] + op(1),
where µM is the true mean cost, G(Z, u) = E{ZiI(Ti ≥ u)}/S(u), for any random
variable or functional Z.
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The mean heart failure free survival time estimator can be approximated by
n
1
2 (µ̂F − µF )
= n−
1
2
n∑
i=1
(T Fi − µF )− n−
1
2
n∑
i=1
∫ L
0
dMCFi (u)
K(u)
{T Fi −GF (T F , u)}+ op(1),
where µF is the true heart failure free survival time, GF (Z, u) = E{ZiI(T Fi ≥
u)}/SF (u), for any random variable or functional Z.
To derive the covariance formula between the cost estimator and the survival time
estimator, we need to calculate the covariance between the two different martingale
processes < dMCi (u), dM
CF
i (u) >. Define
dMC∗i (u) = dN
C∗
i (u)− λC(u)I(Ci ≥ u)du
where NC∗i (u) = I(Ci ≤ u). We can show that
dMCi (u) = I(Ti > u)dM
C∗
i (u),
dMCFi (u) = I(T
F
i > u)dM
C∗
i (u),
and
Var{dMC∗i (u)|F(u)} = I(Ci > u)λC(u)du.
Hence,
Cov{dMCi (u), dMCFi (u)|F(u)}
= I(T > u)I(T F > u)Var{dMC∗i (u)|F(u)}
= Y Fi (u)λ
C(u)du.
The covariance between the mean cost estimator µM and the mean heart failure
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free survival time estimator µF becomes
Cov{n 12 (µ̂M − µM), n 12 (µ̂F − µF )}
= Cov(Mi, T
F
i ) + E
∫ L
0
{T Fi −GF (T F , u)}{Mi −G(M,u)}
Y Fi (u)
K(u)2
λC(u)du
−E
∫ L
0
{T Fi −GF (T F , u)}{Mi(u)−G{M(u), u}}
Y Fi (u)
K(u)2
λC(u)du.
= Cov(Mi, T
F
i ) + E
∫ L
0
[{T Fi −GF (T F , u)}{Mi −G(M,u)}I(T Fi ≥ u)]
λC(u)
K(u)
du
−E
∫ L
0
[{T Fi −GF (T F , u)}{Mi(u)−G{M(u), u}}I(T Fi ≥ u)]
λC(u)
K(u)
du.
= Cov(Mi, T
F
i ) +
∫ L
0
[GF{T FM,u} −GF{M,u}GF (T F , u)]S
F (u)λC(u)
K(u)
du
−
∫ L
0
[GF{T FM(u), u} −GF{M(u), u}GF (T F , u)]S
F (u)λC(u)
K(u)
du
This can be estimated consistently by
1
n
n∑
i=1
∆iMiT
F
i
K̂(Ti)
− 1
n2
n∑
i=1
∆iMi
K̂(Ti)
n∑
i=1
∆Fi T
F
i
K̂F (T Fi )
+
1
n
∫ L
0
dNCF (u)
K̂F (u)2
{ĜF0(T FM,u)− ĜF0(M,u)ĜF0(T F , u)}
− 1
n
∫ L
0
dNCF (u)
K̂F (u)2
{ĜF0{T FM(u), u} − ĜF0{M(u), u}ĜF0(T F , u)},
where
ĜF0(Z, u) =
1
nŜF (u)
n∑
i=1
∆i
K̂(Ti)
ZiI(T
F
i ≥ u), (B.1)
Although some of G can be estimated by
ĜF (Z, u) =
1
nŜF (u)
n∑
i=1
∆Fi
K̂F (Ti)
ZiI(T
F
i ≥ u), (B.2)
which seems to adopt more data information when available, using the same form of
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Ĝ achieves more efficiency in numerical studies. Thus, we suggest to use the same
estimator for G.
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